The viscosity of a monoclonal antibody solution must be monitored and controlled as it can adversely affect product processing, packaging and administration. Engineering low viscosity mAb formulations is challenging as prohibitive amounts of material are required for concentrated solution analysis, and it is difficult to predict viscosity from parameters obtained through low-volume, high-throughput measurements such as the interaction parameter, kD, and the second osmotic virial coefficient, B22. As a measure encompassing the effect of intermolecular interactions on dilute solution viscosity, the Huggins coefficient, kh, is a promising candidate as a parameter measureable at low concentrations, but indicative of concentrated solution viscos...
The ability to design and formulate mAbs to minimize attractive interactions at high concentrations ...
Current trends in market for high dose therapeutic proteins require concentrated liquid formulations...
Current trends in market for high dose therapeutic proteins require concentrated liquid formulations...
From PubMed via Jisc Publications RouterHistory: received 2021-06-04, revised 2021-07-28, accepted 2...
AbstractWeak protein-protein interactions are thought to modulate the viscoelastic properties of con...
High concentration subcutaneous (SC) dosing regimens are desirable for monoclonal antibody (MAb) the...
High concentration subcutaneous (SC) dosing regimens are desirable for monoclonal antibody (MAb) the...
High concentration subcutaneous (SC) dosing regimens are desirable for monoclonal antibody (MAb) the...
Solutions of monoclonal antibodies (mAbs) at high concentration are strongly desirable for subcutane...
Highly concentrated (> 200 mg/mL) monoclonal antibody (mAb) formulations with low viscosities are st...
High protein titers are gaining importance in biopharmaceutical industry. A major challenge in the d...
This electronic version was submitted by the student author. The certified thesis is available in th...
High protein titers are gaining importance in biopharmaceutical industry. A major challenge in the d...
Clinical doses of therapeutic proteins range up to 2 mg/kg bodyweigth per patient and even higher. F...
Development of high concentration liquid formulations is especially attractive for biopharmaceutical...
The ability to design and formulate mAbs to minimize attractive interactions at high concentrations ...
Current trends in market for high dose therapeutic proteins require concentrated liquid formulations...
Current trends in market for high dose therapeutic proteins require concentrated liquid formulations...
From PubMed via Jisc Publications RouterHistory: received 2021-06-04, revised 2021-07-28, accepted 2...
AbstractWeak protein-protein interactions are thought to modulate the viscoelastic properties of con...
High concentration subcutaneous (SC) dosing regimens are desirable for monoclonal antibody (MAb) the...
High concentration subcutaneous (SC) dosing regimens are desirable for monoclonal antibody (MAb) the...
High concentration subcutaneous (SC) dosing regimens are desirable for monoclonal antibody (MAb) the...
Solutions of monoclonal antibodies (mAbs) at high concentration are strongly desirable for subcutane...
Highly concentrated (> 200 mg/mL) monoclonal antibody (mAb) formulations with low viscosities are st...
High protein titers are gaining importance in biopharmaceutical industry. A major challenge in the d...
This electronic version was submitted by the student author. The certified thesis is available in th...
High protein titers are gaining importance in biopharmaceutical industry. A major challenge in the d...
Clinical doses of therapeutic proteins range up to 2 mg/kg bodyweigth per patient and even higher. F...
Development of high concentration liquid formulations is especially attractive for biopharmaceutical...
The ability to design and formulate mAbs to minimize attractive interactions at high concentrations ...
Current trends in market for high dose therapeutic proteins require concentrated liquid formulations...
Current trends in market for high dose therapeutic proteins require concentrated liquid formulations...